| NCT ID | NCT07275476 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jagiellonian University |
| Condition | Fibrin Blood Clot |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-11-28 |
| Primary Completion | 2026-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-11-28 with a primary completion date of 2026-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
1. The structure of fibrin clot and thrombin generation may vary between trimesters of pregnancy. 2. Unfavorably altered fibrin clot properties along with enhanced thrombin generation may lead to the development of complications during pregnancy such as TE and hypertensive disorders. 3. The application of machine learning techniques may help to identify previously undetected phenotypes with increased risk of TE and hypertensive disorders during pregnancy.
Eligibility Criteria
Inclusion Criteria: I. age 18-40 years; II. natural conception (without assisted reproductive techniques). Exclusion Criteria: I. use of hormonal therapy (i.e., oral contraceptives, progestogens) within 3 months before or during pregnancy; II. use of anticoagulants oral/subcutaneous within 3 months before or during pregnancy; III. increased risk factors of VTE (i.e., obesity - body mass index \>30 kg/m2; smoking) or history of VTE; IV. Concomitant diseases, i.e: severe hypertension, diabetes mellitus, autoimmune diseases (i.e., systemic lupus erythematosus, antiphospholipid syndrome); V. congenital or acquired thrombophilia (i.e., mutation factor V Leiden, prothrombin mutation).
Frequently Asked Questions
Who can join the NCT07275476 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Fibrin Blood Clot. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07275476 currently recruiting?
Yes, NCT07275476 is actively recruiting participants. Visit ClinicalTrials.gov or contact Jagiellonian University to inquire about joining.
Where is the NCT07275476 trial being conducted?
This trial is being conducted at Krakow, Poland.
Who is sponsoring the NCT07275476 clinical trial?
NCT07275476 is sponsored by Jagiellonian University. The trial plans to enroll 100 participants.